Home・Elenco Azioni・Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

20.93 4.08

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.82

Massimo

21.03

Metriche Chiave
By Trading Economics
Entrata	24M 30M
Vendite	13M 184M
P/E Media del settore	12.309 57.002
EPS	0.8
Margine di Profitto	16.502
Dipendenti	1,976
EBITDA	12M 45M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+7.38% upside

Dividendi
By Acuity
Utili prossimi	5 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	18M 864M
Apertura precedente	16.85
Chiusura precedente	20.93

Notizie sul Sentiment di mercato

By Acuity

84%

16%

319 / 340 Classifica in Healthcare

Amphastar Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 ago 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

11 ago 2026, 19:56 UTC

News

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

10 ago 2026, 19:36 UTC

News

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

7 ago 2026, 19:51 UTC

News

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

6 ago 2026, 23:02 UTC

News

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

4 ago 2026, 19:51 UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 ago 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31 lug 2026, 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30 lug 2026, 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29 lug 2026, 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28 lug 2026, 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24 lug 2026, 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22 lug 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21 lug 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

20 lug 2026, 19:56 UTC

Amphastar Pharmaceuticals is gaining modestly during Monday's session amid mixed market conditions and geopolitical tensions affecting oil prices and inflation concerns.

Confronto tra pari

Modifica del prezzo

Amphastar Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

7.38% in crescita

Previsioni per 12 mesi

Media 21.67 USD 7.38%

Alto 30 USD

Basso 20 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amphastar Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Amphastar Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

319 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.